Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe

Sheila Terwisscha van Scheltinga*, Reineke A. Schoot, Jonathan C. Routh, Guido Seitz, Simon C. Kao, Bart de Keizer, Barry Shulkin, Roelof van Ewijk, Beth McCarville, Dana Casey, Wendy Allen-Rhoades, Federico Mercolini, Hans Merks, Daniel Orbach, Tejas Kapadia, David O. Walterhouse, Raquel Davila Fajardo, Laura Hiemcke-Jiwa, Christiane Franzius, Federica De CortiVivian Tang, Jonathan Metts, Saphna Oberoi, Christian Vokuhl, Roshni Dasgupta, Suzi Birz, David Rodeberg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Accurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children's Oncology Group (COG), European paediatric Soft tissue sarcoma Study Group (EpSSG), and the Cooperative Weichteilsarkom Studiengruppe (CWS) complicate comparisons. In this article, we aim to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) according to the Consensus Conference Standard Operating Procedure methodology.

Original languageEnglish
Article numbere31538
JournalPediatric Blood and Cancer
Volume72
Issue number4
Early online date23 Jan 2025
DOIs
Publication statusPublished - Apr 2025

Keywords

  • including soft tissue
  • non-rhabdoid
  • pediatric oncology
  • rhabdomyosarcoma
  • sarcomas

Fingerprint

Dive into the research topics of 'Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe'. Together they form a unique fingerprint.

Cite this